HighTower Advisors’s Filana Therapeutics FLNA Stock Holding History

HighTower Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,000	Closed	-$82K	–	3401
2021 Q2	$82K	Buy	+2,000	New	+$107K	﹤0.01%	2840

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighTower Advisors's FLNA Position: Q4 2022 in Review

HighTower Advisors sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 6,320 shares — an estimated $264K sold.

HighTower Advisors first reported a position in FLNA in Q1 2021 and held it in 6 quarters. The position peaked at $1.85M in Q3 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

HighTower Advisors reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
HighTower Advisors sold 6,320 Filana Therapeutics shares in Q4 2022, an estimated $264K.
HighTower Advisors first reported a position in Filana Therapeutics in Q1 2021 and held it in 6 quarters.
HighTower Advisors's Filana Therapeutics position peaked at $1.85M in Q3 2021.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.